Navigation Links
Novagali Pharma Completed a New Phase II With Cyclokat(R) in Dry Eye
Date:4/15/2009

EVRY, France, April 15 /PRNewswire/ -- Novagali Pharma, a French pharmaceutical ophthalmic company, today announces successful completion of a new Phase II clinical study with Cyclokat(R), its formulation of Cyclosporine. The results demonstrate statistically significant improvement with signs and symptoms in patients suffering from moderate-to-severe dry eye syndrome.

For this dry eye clinical trial, Novagali worked with Ora, Inc., a leading global clinical research and development organization located in Andover, MA, USA. This phase II, multi-centre, randomized, double-masked, vehicle controlled study of 132 patients evaluated the safety and efficacy of Cyclokat(R) applied once-a-day over three months. Ora's proprietary Controlled Adverse Environment (CAE) clinical model was used in this study conducted in the US.

Efficacy was observed post-CAE as well as pre-CAE (environmental comparisons following selection and enrollment of patients utilizing the CAE). Cyclokat(R) demonstrated significant treatment effect on multiple efficacy variables for both signs and symptoms at Month 1 and Month 3. . These findings confirm potential clinical interest of Cyclokat(R) for the treatment of dry eye syndrome.

"We are very enthusiastic about the results of this new trial demonstrating efficacy on both dry eye signs and symptoms" said Jerome Martinez, CEO of Novagali "These are promising results which make us confident in the success of our ongoing Phase III which outcomes are expected 4Q2009".

A pivotal Phase III trial is ongoing in Europe and patient recruitment has been already completed.

Cyclokat(R) is a proprietary ophthalmic emulsion enabling an optimal penetration of Cyclosporine in tissues of the eye surface that benefit from Novasorb(R), Novagali(R) cationic emulsion technology.

About Novagali Pharma : http:/
'/>"/>

SOURCE Novagali Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Novagali Pharma Presents Results of its Innovative Latanoprost Formulation for Glaucoma
2. Novagali Pharma Successfully Enrolls First Patient in U.S. Phase I Clinical Study with CORTIJECT(R) for Diabetic Macular Edema
3. Osprey Pharmaceuticals U.S.A., Inc. Initiates Phase Ib Clinical Trial in IgA Nephropathy
4. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
5. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
6. Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
7. Strativa Pharmaceuticals Provides Product Pipeline Update
8. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
9. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
10. Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Investor-Edge has initiated coverage on ... FOLD ), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX ... Idera Pharmaceuticals Inc. (NASDAQ: IDRA ), and ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,419.48, up 2.40%, the Dow Jones ...
(Date:10/22/2014)... 22, 2014   Reproductive Medicine Associates of ... the field of infertility, presents new clinical research ... The research abstract, released during the 70 th ... meeting in Honolulu, Hawaii , ... defect (SGD) pre-implantation genetic diagnosis (PGD). ...
(Date:10/22/2014)... , Oct. 22, 2014 AVACEN Medical announced ... received 510 (k) OTC clearance by the U.S. Food ... to be marketed over the Internet for: the ... spasms; and minor strains and sprains . ... AVACEN 100 (MSRP $2495) is a sophisticated medical device ...
Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 2New IVF Research Highlights Improved Genetic Screening Approach To Help Parents Have Healthier Babies 3AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
(Date:10/22/2014)... Healthcare professionals who are looking for ... home or on-the-go via laptops, tablets or mobile ... premium Seminar-on-Demand CE courses. The new courses add ... hours of CE course offerings, allowing therapy ... such a diverse library, there’s something for everyone. ...
(Date:10/22/2014)... MA (PRWEB) October 22, 2014 ... new solutions for the treatment of bacterial infections, microbial ... Sinskey has joined its board of directors. , ... and Engineering Systems at The Massachusetts Institute of Technology, ... MIT faculty since 1968. Dr. Sinskey also holds positions ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 With a ... Gov. Charlie Crist made a brief fundraising stop at ... on Thursday. , Fresh from a debate last night ... take the stage for the first seven minutes because ... former governor described the incident in one word: "weird." ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
Breaking Medicine News(10 mins):Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4
... days, experts say, , , THURSDAY, Jan. 3 (HealthDay News) -- ... be passed from one person to another through contact with ... U.S. health officials report. , The virus, which is common ... of vomiting and diarrhea in the United States, is often ...
... Examined, ARLINGTON HEIGHTS, Ill., Jan. 3 ... new,knowledge about the effects of silicone breast implants. ... the official,medical journal of the American Society of ... impact and health concerns of silicone,breast implants., ...
... Abbott (NYSE: ABT ),will announce its financial ... 2007, on Wednesday, Jan. 23, 2008, before the market ... live webcast of the earnings,conference call at 8 a.m. ... Abbott,s Investor Relations Web site at, http://www.abbottinvestor.com . An ...
... who,purchased or were given "home-canned" soup or other ... County, should not open the jars due,to the ... B.,Johnson said today., Consumers who obtained canned ... Department of Health, toll-free, at,877-PA-HEALTH., The state ...
... Idaho, Jan. 3 RxElite, Inc. (OTC,Bulletin Board: ... prescription drug products, announced today that a registration,statement ... stockholders,was declared effective by the Securities and Exchange ... provided for informational purposes only, and does not,represent ...
... body,s health, researchers say , , THURSDAY, Jan. 3 (HealthDay News) ... a placebo to a patient during their years of practice, ... in the study also said they believed in the power ... that can affect health, the researchers said. , A ...
Cached Medicine News:Health News:Stomach Flu Spread By Contaminated Computer Keyboards 2Health News:Stomach Flu Spread By Contaminated Computer Keyboards 3Health News:ASPS Studies Re-Evaluate Psychological Benefits and Health Concerns of Silicone Breast Implants 2Health News:Health Department Warns Consumers of Home-Canned Soup Linked to Potter County Restaurant 2Health News:RxElite Registration Statement Declared Effective by Securities and Exchange Commission 2Health News:Almost Half of Doctors Have Prescribed Placebos 2
... The economical way to order tips. ... of 1000 tips). Also available in easy-to-open, ... pack. Bulk Packs are sealed with a ... for quick access to Gilsons Diamond Tips. ...
10 L, Bulk Recommended for 5 & 10 L pipettes. Ideal for pipetting into long, narrow tubes or deep well plates....
... The Theken eDISC is a revolutionary ... ability to assess and manage their patients. ... motion separates the eDISC from 1st and ... motions and loads of the lumbar spine, ...
This extended 10 ul combats contamination by keeping your pipettor out of 1.5 ul and 2.0 ul tubes. Utilizes MicroPoint design and 2 ul reference mark....
Medicine Products: